![Ed Mathers Mathers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ed Mathers Mathers
Director/Board Member at
SYNLOGIC, INC.
Net worth: 2 M $ as of 2026-06-29
Profile
Mr. Edward T.
Mathers is an Independent Director at Senti Biosciences Holdings, Inc., an Independent Director at OnKure Therapeutics, Inc., an Independent Director at MBX Biosciences, Inc., an Independent Director at Affinia Therapeutics, Inc., an Independent Director at Trevi Therapeutics, Inc., an Independent Director at Senti Biosciences, Inc., an Independent Director at Synlogic, Inc., a General Partner at New Enterprise Associates, Inc., a Partner at NEA Management Co. LLC and a Member at North Carolina State University College of Sciences Foundation.
He is on the Board of Directors at Senti Biosciences Holdings, Inc., OnKure Therapeutics, Inc., MBX Biosciences, Inc., Affinia Therapeutics, Inc., Trevi Therapeutics, Inc., Senti Sub I, Inc., Senti Biosciences, Inc., Synlogic, Inc., Code Biotherapeutics, Inc., Envisia Therapeutics, Inc., Inversago Pharma, Inc., Shape Therapeutics, Inc., Sorriso Pharmaceuticals, Inc., SpliceBio SL and Synlogic Operating Co., Inc. He received his undergraduate degree from North Carolina State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-11 | 21,168 ( 0.03% ) | 2 M $ | 2026-06-29 | |
0.04% | 2026-06-03 | 15,670 ( 0.04% ) | 71 455 $ | 2026-06-29 |
| 2026-06-02 | 0 ( -.--% ) | - $ | 2026-06-29 | |
SYNLOGIC INC -.--% | 2026-03-30 | 0 ( -.--% ) | - $ | 2026-06-29 |
| 2026-06-03 | 0 ( -.--% ) | - $ | 2026-06-29 | |
-.--% | 2026-03-26 | 0 ( -.--% ) | - $ | 2026-06-29 |
Ed Mathers Mathers active positions
| Companies | Position | Start |
|---|---|---|
| SYNLOGIC, INC. | Director/Board Member | 2012-09-30 |
| TREVI THERAPEUTICS, INC. | Director/Board Member | 2017-06-30 |
| MBX BIOSCIENCES, INC. | Director/Board Member | 2020-06-30 |
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Director/Board Member | 2016-06-30 |
North Carolina State University College of Sciences Foundation | Corporate Officer/Principal | - |
Shape Therapeutics, Inc.
 Shape Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, small molecule, topical histone deacetylase inhibitor for the treatment of cutaneous t-cell lymphoma | Director/Board Member | - |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Director/Board Member | - |
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Director/Board Member | 2016-06-30 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Director/Board Member | 2020-02-29 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Ed Mathers Mathers
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Ed Mathers Mathers
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
46
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 46 |
|---|---|
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Kémia, Inc.
 Kémia, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule therapeutics | Health Technology |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
Satori Pharmaceuticals, Inc.
 Satori Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for alzheimer's disease | Health Technology |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops particle-based vaccines and therapeutics for prevention and treatment of human disease | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for rare liver diseases | Health Technology |
Ziarco, Inc. | |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements. | Finance |
North Carolina State University
 North Carolina State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Health Technology |
Southeast BIO | |
North Carolina State University College of Sciences Foundation | |
Glaxo Wellcome, Inc.
 Glaxo Wellcome, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparations | Health Technology |
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Commercial Services |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes medicines | Health Technology |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Health Technology |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Develops peptide therapeutics for the treatment of gastrointestinal diseases | Health Technology |
Empower Energies Clean Infrastructure LLC
 Empower Energies Clean Infrastructure LLC SemiconductorsElectronic Technology Designs and manufactures solar energy systems | Electronic Technology |
Trevi Therapeutics, Inc.
 Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Provides therapeutics targeting inflammatory and allergic diseases | Health Technology |
ObsEva SA
 ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity | Health Technology |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics targeting skin inflammatory and allergic diseases | Health Technology |
Reneo Pharmaceuticals, Inc.
 Reneo Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases | Health Technology |
Inozyme Pharma, Inc.
 Inozyme Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines | Health Technology |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Synlogic, Inc.
 Synlogic, Inc. Financial ConglomeratesFinance Operates as a shell company | Finance |
Akouos, Inc.
 Akouos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a genetic medicine company that develops adeno-associated viral vector-based gene therapies for sensorineural hearing loss | Commercial Services |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology Engages in research and development in biotechnology | Health Technology |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
Shape Therapeutics, Inc.
Shape Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, small molecule, topical histone deacetylase inhibitor for the treatment of cutaneous t-cell lymphoma | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
Sorriso Pharmaceuticals, Inc.
 Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company advancing disease-modifying antibodies for the treatment of inflammatory disease | Health Technology |
New Enterprise Associates, Inc.
 New Enterprise Associates, Inc. Financial ConglomeratesFinance Provides investment services | Finance |
- Stock Market
- Insiders
- Ed Mathers Mathers
